Whole Cell (wP) Hexavalent and “availability of vaccine” OR “resource use” OR cost-effectiveness
Kasi, S. G. (2021). IAP Q & A on Vaccines & Vaccinology. Jaypee Brothers Medical Publishers. [Book]
Nakabembe, E., Greenland, M., Amaral, K., Abu-Raya, B., Amone, A., Andrews, N., Cantrell, L., Lesne, E., Gorringe, A., & Halkerston, R. (2025). Safety and immunogenicity of an acellular pertussis vaccine containing genetically detoxified pertussis toxin administered to pregnant women living with and without HIV and their newborns (WoMANPOWER): A randomised controlled trial in Uganda. The Lancet Global Health, 13(1), e81–e97.https://pdf.sciencedirectassets.com/286970/
Osei, C. K., Nketiah-Amponsah, E., Fenny, A. P., & Otchere, F. (2024). Vaccine pricing and production capacity in Africa: Can Africa move beyond pooled procurement in the face of a future pandemic? Global Health Journal. https://doi.org/10.1016/j.glohj.2024.11.001
Russell, L. B., Sobanjo-ter Meulen, A., & Toscano, C. M. (2021). Evaluating the cost-effectiveness of maternal pertussis immunization in low-and middle-income countries: A review of lessons learnt. In Vaccine (Vol. 39, Issue 1, pp. 121–124). Elsevier. https://doi.org/10.1016/j.vaccine.2020.10.054
Seinfeld, J., Rosales, M. L., Sobrevilla, A., & López Yescas, J. G. (2022). Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru. BMC Health Services Research, 22(1), 651. https://doi.org/10.1186/s12913-022-08006-1